Obsessive-Compulsive Disorder Market Report 2026

The obsessive-compulsive disorder market size has grown strongly in recent years. It will grow from $0.67 billion in 2025 to $0.73 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to limited availability of specialized ocd medications, low awareness of therapy options, stigma surrounding mental health disorders, high cost of treatment, reliance on traditional therapy methods.

The obsessive-compulsive disorder market size is expected to see strong growth in the next few years. It will grow to $1 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to advancements in ai-driven mental health tools, increasing demand for telepsychiatry services, rising adoption of personalized treatment approaches, growing r&d in novel ocd drugs, expanding mental health awareness and government support programs. Major trends in the forecast period include rising adoption of digital therapeutics for ocd management, increasing integration of ai-based symptom tracking tools, growing focus on personalized medicine and targeted therapies, rising use of telepsychiatry and remote patient monitoring, increasing research on genomic and neurobiological drivers of ocd.

The rising prevalence of mental illness is expected to drive growth in the obsessive-compulsive disorder (OCD) market in the coming years. Mental illness encompasses a broad range of conditions affecting mood, thinking, behavior, and overall functioning, and its increase is fueled by heightened awareness and diagnosis, lifestyle changes, chronic stress, global crises, and social, economic, and environmental pressures. OCD contributes to understanding the complex mechanisms of mental illness, advancing diagnosis, treatment, and management approaches for wider mental health conditions. For example, in May 2024, according to the American Psychiatric Association, a US-based professional organization, 43% of adults reported experiencing elevated levels of anxiety, up from 37% in 2023 and 32% in 2022. This rising burden of mental health conditions is propelling the OCD market forward.

Major companies in the OCD market are developing advanced mental health treatment solutions to improve therapeutic outcomes. Mental health treatment includes interventions such as medications, counseling, cognitive behavioral therapy, and lifestyle management strategies. For instance, in October 2023, Newport Healthcare, a US-based healthcare company, launched its Obsessive-Compulsive Disorder Treatment Program targeting teens and young adults. The program integrates evidence-based therapies, including Cognitive Behavioral Therapy (CBT), Exposure and Response Prevention (ERP), and family-focused interventions, alongside mindfulness, physical wellness, and life skills development, providing a comprehensive care model designed for holistic recovery.

In August 2023, Talkiatry, a US-based healthcare provider, partnered with NOCD, a US-based mental health technology company, to advance OCD care through integrated services. This partnership combines specialized ERP therapy with psychiatric care, aiming to streamline treatment, enhance accessibility, and improve patient outcomes for individuals living with OCD.

Major companies operating in the obsessive-compulsive disorder market are Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Zydus Cadila, Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Par Pharmaceutical, GlaxoSmithKline plc, H Lundbeck A/S, Johnson & Johnson Services Inc, Takeda Pharmaceutical Company Limited, Viatris Inc, Apotex Inc, Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Roche Holding AG, Alvogen Inc, Wockhardt Ltd, Sebela Pharmaceuticals Inc, Otsuka Pharmaceutical Co Ltd.

North America was the largest region in the obsessive-compulsive disorder market in 2025. The regions covered in the obsessive-compulsive disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the obsessive-compulsive disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the obsessive-compulsive disorder market by increasing costs of imported pharmaceuticals, digital therapeutic tools, and monitoring devices, particularly affecting hospitals, specialty clinics, and retail pharmacies in north america, europe, and asia-pacific. While these tariffs may slow adoption in some regions, they also encourage local manufacturing, innovation in therapy tools, and cost-optimized solutions for ocd management.

The obsessive-compulsive disorder market research report is one of a series of new reports that provides obsessive-compulsive disorder market statistics, including obsessive-compulsive disorder industry global market size, regional shares, competitors with a obsessive-compulsive disorder market share, detailed obsessive-compulsive disorder market segments, market trends and opportunities, and any further data you may need to thrive in the obsessive-compulsive disorder industry. This obsessive-compulsive disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Obsessive-compulsive disorder (OCD) is a mental health condition marked by recurring, intrusive thoughts (obsessions) and repetitive behaviors or mental acts (compulsions) performed to reduce anxiety. These behaviors often disrupt daily life and cause significant distress, with common themes including cleanliness, orderliness, and fear of harm. Treatment generally involves a combination of therapy and medication.

The main drug classes for obsessive-compulsive disorder include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), serotonin antagonists and reuptake inhibitors (SARIs), and tricyclic antidepressants (TCAs). SSRIs function by increasing serotonin levels in the brain and preventing its reabsorption into nerve cells. They are commonly prescribed for conditions such as major depressive disorder, anxiety disorders, and attention deficit hyperactivity disorder (ADHD). These medications are distributed through hospital pharmacies, retail pharmacies, and other channels, and are used by end users including hospitals, specialty clinics, and other healthcare facilities.

The obsessive-compulsive disorder market includes revenues earned by entities by providing services such as diagnosing, treating, and managing mental health conditions and related products including benzodiazepines, neurostimulation devices, and ERP therapy tools. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.